MiMedx Group (MDXG) Investor presentation summary

Strategy and market opportunity

• Strategic priorities: diversify products, increase Surgical growth, expand market opportunities and shift revenue mix toward more stable, opportunistic markets.

• U.S. market includes ~92 million annual surgical procedures, including ~23 million general surgery procedures; Sanara acquisition expected to unlock >$4B in incremental addressable markets.

• Surgical sales grew 15% based on LTM Q3 2026 vs. LTM Q3 2025; eight surgical studies underway, with five published since May 2025.

• Wound care opportunity includes >10 million people in the U.S. with chronic or hard-to-heal wounds and ~$150B in global wound care expenditure.

Proposed Sanara transaction

• Proposed purchase price of $35 per share, a 46% premium to Sanara’s 30-day VWAP as of July 28, 2026; consideration includes $33 cash and 0.4735 shares, valued at $2 per share.

• Transaction enterprise value ~$350M; financing includes a new $300M, six-year senior secured term loan at SOFR + 6.25%, alongside cash on hand.

• First full year post-close: combined revenue expected to approach $400M, adjusted EBITDA margin above 20%, and >$20M in annualized run-rate cost synergies expected in 2027.

• Sanara reported 2025 revenue of $103M, 19% YoY growth, 93% gross margin and $17M adjusted EBITDA; its 7-year revenue CAGR was 51%.

• Sanara shareholder approval obtained September 30; FTC clearance remained the last major closing hurdle.

Clinical evidence and product platform

• AMNIOFIX recipients had colorectal anastomotic leak rates of 1.9% vs. 3.8% for NSQIP and 2.3% vs. 6.2% for PHD; reported reductions were 48% and 63%, respectively.

• AMNIOFIX 30-day readmissions were 5.7% vs. 9.4% for NSQIP and 11.1% for PHD; reported reductions were 40% and 49%, respectively.

• Surgical research spans liver transplant, esophageal reconstruction, vascular, colorectal, breast reduction, spine, ACL repair and prostatectomy; several studies are published or progressing through analysis and review.

• Placental product platform combines published clinical evidence, a national tissue donation network, proprietary processing, 200+ patents and customer support tools through MIMEDX Connect.